Abstract
Vascular endothelial growth factor (VEGF) is a main regulator of blood vessel growth and plays an important role in promoting endothelial survival and maintaining the microvasculature. The kidney is a highly vascularized organ and has two important microvasculatures; glomerular and peritubular capillaries. Loss of these capillaries is strongly associated with the progression of chronic kidney disease (CKD) to end-stage renal disease. In several kidney disease animal models, VEGF expression in the kidney is decreased and administration of VEGF is protective. Recent clinical observations revealed that blocking VEGF by endogenous inhibitor (soluble Flt-1) in preeclampsia and monoclonal antibody against VEGF in cancer patients cause proteinuria and renal dysfunction. However, plasma VEGF levels in diabetic nephropathy patients are increased and blocking VEGF improved diabetic nephropathy in animal models. Increased plasma VEGF levels have been reported in CKD patients. Deleterious effects of VEGF have been demonstrated in atherosclerosis and sepsis, which are frequent complications in CKD patients. Although administrating VEGF or novel drugs that activate VEGF pathway may improve the progression of CKD, careful monitoring will be required when CKD patients have complications of diabetes, atherosclerosis or sepsis.
Keywords: Vascular endothelial growth factor, chronic kidney disease, diabetic nephropathy, sepsis, atherosclerosis
Current Vascular Pharmacology
Title: Role of Vascular Endothelial Growth Factor in Kidney Disease
Volume: 8 Issue: 1
Author(s): Kent Doi, Eisei Noiri and Toshiro Fujita
Affiliation:
Keywords: Vascular endothelial growth factor, chronic kidney disease, diabetic nephropathy, sepsis, atherosclerosis
Abstract: Vascular endothelial growth factor (VEGF) is a main regulator of blood vessel growth and plays an important role in promoting endothelial survival and maintaining the microvasculature. The kidney is a highly vascularized organ and has two important microvasculatures; glomerular and peritubular capillaries. Loss of these capillaries is strongly associated with the progression of chronic kidney disease (CKD) to end-stage renal disease. In several kidney disease animal models, VEGF expression in the kidney is decreased and administration of VEGF is protective. Recent clinical observations revealed that blocking VEGF by endogenous inhibitor (soluble Flt-1) in preeclampsia and monoclonal antibody against VEGF in cancer patients cause proteinuria and renal dysfunction. However, plasma VEGF levels in diabetic nephropathy patients are increased and blocking VEGF improved diabetic nephropathy in animal models. Increased plasma VEGF levels have been reported in CKD patients. Deleterious effects of VEGF have been demonstrated in atherosclerosis and sepsis, which are frequent complications in CKD patients. Although administrating VEGF or novel drugs that activate VEGF pathway may improve the progression of CKD, careful monitoring will be required when CKD patients have complications of diabetes, atherosclerosis or sepsis.
Export Options
About this article
Cite this article as:
Doi Kent, Noiri Eisei and Fujita Toshiro, Role of Vascular Endothelial Growth Factor in Kidney Disease, Current Vascular Pharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157016110790226606
DOI https://dx.doi.org/10.2174/157016110790226606 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry Advances in Drug Safety
Current Pharmaceutical Design Adipokines and Myokines: A Pivotal Role in Metabolic and Cardiovascular Disorders
Current Medicinal Chemistry Oxidative-Nitrosative Stress In Hypertension
Current Vascular Pharmacology The Journey From Metabolic Profiling to Biomarkers: The Potential of NMR Spectroscopy Based Metabolomics in Neurodegenerative Disease Research
Current Metabolomics Vasopeptidase Inhibition for Blood Pressure Control: Emerging Experience
Current Pharmaceutical Design Inhibitors of the TGF-β Superfamily and their Clinical Applications
Mini-Reviews in Medicinal Chemistry Relation Between URIC Acid Levels and Subclinical Hypothyroidism in Diabetic Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Time Dependent Distribution of MicroRNA 144 after Intravenous Delivery
MicroRNA Cross-Talk Between TGF-β and NADPH Oxidases During Liver Fibrosis and Hepatocarcinogenesis
Current Pharmaceutical Design Inflammasome Activation in Chronic Glomerular Diseases
Current Drug Targets Radioprotective Effect of Febuxostat Against Testicular Damage Induced by Ionizing Radiation in Mice
Current Radiopharmaceuticals Vitamins and Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipid Composition of Cell Membranes and Its Relevance in Type 2 Diabetes Mellitus
Current Diabetes Reviews P2X Receptors and Diabetes
Current Medicinal Chemistry Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design The Effects of Angiotensin II Signaling Blockade on Platelet Activity in Subjects with Hypertension
Current Hypertension Reviews Acute Kidney Injury in Pediatric Heart Failure
Current Cardiology Reviews